# Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.

> **NCT03231124** · PHASE1 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 26 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** LEO 32731
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03231124
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-25
- **Primary completion:** 2017-08-22
- **Final completion:** 2017-08-22
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2021-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03231124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03231124, "Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03231124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*